Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

• Status: Recruiting
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jan Lycke
• Treatments: Teriflunomide

Criteria

Inclusion Criteria:

• patients with multiple sclerosis treated with teriflunomide 14 mg for at least 6 months

Exclusion Criteria:

• other immunosuppressive or immunomodulating drugs, other CNS diseases